Paclitaxel (PTX)

DRUG3 trials

Sponsors

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Bristol-Myers Squibb, Skane University Hospital

Conditions

Breast CancerHIV-1 InfectionKidney DiseasesVascular Diseases

Phase 3

Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS

CompletedNCT01435018

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsHIV-1 Infection

Start: 2013-10-01End: 2019-08-29Updated: 2021-10-20

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

CompletedNCT04109066

Bristol-Myers SquibbBreast Cancer

Start: 2019-11-18End: 2023-12-27Updated: 2025-01-08

Unknown Phase

Drug Eluting Balloon (DEB) vs Plain Old Balloon Angioplasty (POBA) in the Treatment of Failing Dialysis Access

CompletedNCT05173857

Skane University HospitalKidney Diseases, Vascular Diseases

Start: 2014-03-01End: 2018-07-31Updated: 2022-01-14

Related Papers

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

2025-01-2144 citations

Checkpoint inhibition for early-stage hormone receptor-positive breast cancer.

2024-06-245 citations

Abstract GS01-01: Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL

Cancer Research2024-05-0224 citations

A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.

Journal of Clinical Oncology2020-05-2024 citations

Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.

2020-03-0562 citations